{"id":12331,"date":"2025-04-04T15:35:35","date_gmt":"2025-04-04T13:35:35","guid":{"rendered":"https:\/\/www.msd.ch\/de\/?post_type=story&p=12331"},"modified":"2026-02-16T20:50:00","modified_gmt":"2026-02-16T19:50:00","slug":"gemeinsam-gegen-brustkrebs","status":"publish","type":"story","link":"https:\/\/www.msd.ch\/de\/stories\/gemeinsam-gegen-brustkrebs\/","title":{"rendered":"Gemeinsam gegen Brustkrebs\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0"},"content":{"rendered":"\n
\n
\n \n \n Unternehmen<\/small>\n <\/a>\n \n \n

\n Gemeinsam gegen Brustkrebs\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n <\/h1>\n

Brustkrebs ist die h\u00e4ufigste Krebserkrankung bei Frauen. Je fr\u00fcher Brustkrebs erkannt und behandelt wird, desto gr\u00f6sser sind die Heilungschancen. Bei MSD setzen wir uns daf\u00fcr ein, die Fr\u00fcherkennung zu st\u00e4rken. Deshalb haben wir 2022 den PINK CUBE initiiert – eine kontinuierlich wachsende Brustkrebs-Aufkl\u00e4rungsinitiative. Wir sind stolz, dass PINK CUBE mit zwei Preisen ausgezeichnet wurde.<\/p>\n <\/div>\n\n

\n

4. April 2025<\/p>\n

\n

Share this article<\/p>\n

\n \nFacebook icon<\/title><\/svg>\n<\/a><\/p>\n

\n\n\n\n\t.st0{fill:#00857C;}\n\n\nX icon<\/title><\/svg>\n<\/a><\/p>\n

\n \nLinkedin icon<\/title><\/svg>\n<\/a><\/p>\n

\n \nEmail icon<\/title><\/svg>\n<\/a><\/p>\n <\/div>\n <\/div>\n\n
\n
\n
\n \n \n \n \n \"PINK\n <\/picture>\n\n <\/figure>\n \n <\/div>\n <\/div>\n\n
\n
\n
\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n\n\n\n

PINK CUBE Test Your Breast wurde an der 6. Nacht des Sponsorings im Kunsthaus Z\u00fcrich im Beisein von rund 280 G\u00e4sten mit dem renommierten Publikumspreis und dem Responsibility Award von SPONSORING SCHWEIZ ausgezeichnet. Diese Auszeichnung w\u00fcrdigt PINK CUBE Test Your Breast als eine einzigartige und innovative Initiative mit starken Partnerschaften und Sponsoren mit einem gemeinsamen Ziel: Brustkrebs bek\u00e4mpfen. <\/p>\n\n\n\n

PINK CUBE Test Your Breast<\/h2>\n\n\n\n

PINK CUBE Test Your Breast ist eine einzigarte Initiative zur Sensibilisierung der Bev\u00f6lkerung f\u00fcr Brustkrebs und die bedeutende Rolle der Fr\u00fcherkennung. Im PINK CUBE bieten Gyn\u00e4kolog:innen kostenlose Beratungen und Tastuntersuchungen der Brust an. Die Besuchenden lernen, wie sich ein Knoten anf\u00fchlt und wie sie ihre Brust selbst abtasten k\u00f6nnen, um Ver\u00e4nderungen zu erkennen.<\/p>\n\n\n\n

Ausserdem engagiert sich PINK CUBE Test Your Breast durch Medienarbeit und den Dialog mit der Politik daf\u00fcr, dass alle Kantone in der Schweiz ein organisiertes Mammografie-Screening-Programm einf\u00fchren.<\/p>\n\n\n\n

<\/div>\n\n\n\n
\n
\n
\"\"<\/figure>\n<\/div>\n\n\n\n
\n
\"\"<\/figure>\n<\/div>\n<\/div>\n\n\n\n
<\/div>\n\n\n\n
<\/div>\n\n\n\n
\n
\n

Resultate 2024<\/h2>\n\n\n\n

Anl\u00e4sslich des Brustkrebsaufkl\u00e4rungsmonats Oktober 2024 besuchte der pinke Container f\u00fcnf Kantone und erreichte mit seiner wichtigen Botschaft zur Fr\u00fcherkennung in den Medien \u00fcber 2.7 Millionen Menschen. <\/p>\n\n\n\n

Fast 500 Personen liessen sich im PINK CUBE untersuchen, bei 32 Frauen und 2 M\u00e4nnern wurden m\u00f6gliche Anzeichen f\u00fcr Brustkrebs festgestellt. Gleichzeitig trug PINK CUBE zu Fortschritten bei politischen Diskussionen zur Einf\u00fchrung von Mammografie-Screening-Programmen bei. <\/p>\n\n\n\n

Diese Erfolge waren nur durch partnerschaftliche Zusammenarbeit und die Unterst\u00fctzung durch Multi-Sponsoring der Unternehmen MSD, Gilead, Roche, Exact Sciences, Novartis, Astra Zeneca und Eli Lilly m\u00f6glich.<\/p>\n<\/div>\n\n\n\n

\n
\"\"<\/figure>\n<\/div>\n<\/div>\n\n\n\n
<\/div>\n\n\n\n
\n
\n
\"Dimitri
Dimitri Gitas, Managing Director MSD Schweiz<\/figcaption><\/figure><\/div><\/div>\n\n\n\n
\n

<\/p>\n\n\n\n

\u201eWir sind stolz, diese wichtige Brustkrebsaufkl\u00e4rungsinitiative ins Leben gerufen zu haben und sie weiterhin als Hauptsponsor zu unterst\u00fctzen\u201c, sagt Dimitri Gitas, Managing Director von MSD Schweiz. \u201eDer Erfolg des PINK CUBE zeigt deutlich, dass ein gleichberechtigter Zugang zur Krebspr\u00e4vention und Fr\u00fcherkennung notwendig ist \u2013 ein Ziel, das durch eine nationale Krebsstrategie erreicht werden kann.\u201c<\/p>\n<\/div>\n<\/div>\n\n\n\n

<\/div>\n\n\n\n

Kosten\u00fcbernahme der Mammografie im Fr\u00fcherkennungsprogramm<\/h2>\n\n\n\n

Wenn eine Untersuchung im Rahmen eines Fr\u00fcherkennungsprogramms durchgef\u00fchrt wird, werden die Kosten von der Grundversicherung \u00fcbernommen, ohne Anrechnung an die Franchise. Die teilnehmenden Frauen bezahlen nur den Selbstbehalt von zehn Prozent (ca. 20 Franken). Frauen ab 50 erhalten alle zwei Jahre per Post Informationen und eine Einladung zur Fr\u00fcherkennungsmammografie. <\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n
<\/div>\n\n\n\n

PINK CUBE Test Your Breast 2025 Roadshow<\/h2>\n\n\n\n

Im September und Oktober 2025 wird der PINK CUBE in den 11 Kantonen sein, die noch kein Mammografie-Screening-Programm eingef\u00fchrt haben.<\/p>\n\n\n\n

Weitere Informationen: www.pinkcube-testyourbreast.ch<\/a><\/p>\n\n\n\n

<\/div>\n\n\n\n

CH-NON-02963, 04\/2025<\/sup><\/p>\n\n\n\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

PINK CUBE Test Your Breast wurde an der 6. Nacht des Sponsorings im Kunsthaus Z\u00fcrich im Beisein von rund 280 G\u00e4sten mit dem renommierten Publikumspreis und dem Responsibility Award von SPONSORING SCHWEIZ ausgezeichnet. Diese Auszeichnung w\u00fcrdigt PINK CUBE Test Your Breast als eine einzigartige und innovative Initiative mit starken Partnerschaften und Sponsoren mit einem gemeinsamen […]<\/p>\n","protected":false},"featured_media":12343,"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"footnotes":""},"tags":[50],"content_topic":[51],"admin_field":[],"class_list":["post-12331","story","type-story","status-publish","has-post-thumbnail","hentry","tag-unternehmen","content_topic-unternehmen"],"yoast_head":"\nGemeinsam gegen Brustkrebs\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 - msd.ch<\/title>\n<meta name=\"description\" content=\"PINK CUBE Test Your Breast wurde mit dem renommierten Publikumspreis und dem Responsibility Award von SPONSORING SCHWEIZ ausgezeichnet\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.msd.ch\/de\/stories\/gemeinsam-gegen-brustkrebs\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gemeinsam gegen Brustkrebs\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 - msd.ch\" \/>\n<meta property=\"og:description\" content=\"PINK CUBE Test Your Breast wurde mit dem renommierten Publikumspreis und dem Responsibility Award von SPONSORING SCHWEIZ ausgezeichnet\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.msd.ch\/de\/stories\/gemeinsam-gegen-brustkrebs\/\" \/>\n<meta property=\"og:site_name\" content=\"msd.ch\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-16T19:50:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.msd.ch\/de\/wp-content\/uploads\/sites\/88\/2025\/04\/sponsoring-gv-award_181.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"7395\" \/>\n\t<meta property=\"og:image:height\" content=\"4930\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.msd.ch\/de\/stories\/gemeinsam-gegen-brustkrebs\/\",\"url\":\"https:\/\/www.msd.ch\/de\/stories\/gemeinsam-gegen-brustkrebs\/\",\"name\":\"Gemeinsam gegen Brustkrebs\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 - msd.ch\",\"isPartOf\":{\"@id\":\"https:\/\/www.msd.ch\/de\/#website\"},\"datePublished\":\"2025-04-04T13:35:35+00:00\",\"dateModified\":\"2026-02-16T19:50:00+00:00\",\"description\":\"PINK CUBE Test Your Breast wurde mit dem renommierten Publikumspreis und dem Responsibility Award von SPONSORING SCHWEIZ ausgezeichnet\",\"breadcrumb\":{\"@id\":\"https:\/\/www.msd.ch\/de\/stories\/gemeinsam-gegen-brustkrebs\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.msd.ch\/de\/stories\/gemeinsam-gegen-brustkrebs\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.msd.ch\/de\/stories\/gemeinsam-gegen-brustkrebs\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Stories\",\"item\":\"https:\/\/www.msd.ch\/de\/stories-archive\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gemeinsam gegen Brustkrebs\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.msd.ch\/de\/#website\",\"url\":\"https:\/\/www.msd.ch\/de\/\",\"name\":\"msd.ch\",\"description\":\"MSD erforscht und entwickelt Medikamente und Impfstoffe, die Leben retten und die Gesundheit von Patienten verbessern sollen. In der Schweiz setzen sich 1000 Mitarbeitende in Luzern und Z\u00fcrich daf\u00fcr ein.\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.msd.ch\/de\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Gemeinsam gegen Brustkrebs\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 - msd.ch","description":"PINK CUBE Test Your Breast wurde mit dem renommierten Publikumspreis und dem Responsibility Award von SPONSORING SCHWEIZ ausgezeichnet","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.msd.ch\/de\/stories\/gemeinsam-gegen-brustkrebs\/","og_locale":"en_US","og_type":"article","og_title":"Gemeinsam gegen Brustkrebs\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 - msd.ch","og_description":"PINK CUBE Test Your Breast wurde mit dem renommierten Publikumspreis und dem Responsibility Award von SPONSORING SCHWEIZ ausgezeichnet","og_url":"https:\/\/www.msd.ch\/de\/stories\/gemeinsam-gegen-brustkrebs\/","og_site_name":"msd.ch","article_modified_time":"2026-02-16T19:50:00+00:00","og_image":[{"width":7395,"height":4930,"url":"https:\/\/www.msd.ch\/de\/wp-content\/uploads\/sites\/88\/2025\/04\/sponsoring-gv-award_181.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.msd.ch\/de\/stories\/gemeinsam-gegen-brustkrebs\/","url":"https:\/\/www.msd.ch\/de\/stories\/gemeinsam-gegen-brustkrebs\/","name":"Gemeinsam gegen Brustkrebs\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 - msd.ch","isPartOf":{"@id":"https:\/\/www.msd.ch\/de\/#website"},"datePublished":"2025-04-04T13:35:35+00:00","dateModified":"2026-02-16T19:50:00+00:00","description":"PINK CUBE Test Your Breast wurde mit dem renommierten Publikumspreis und dem Responsibility Award von SPONSORING SCHWEIZ ausgezeichnet","breadcrumb":{"@id":"https:\/\/www.msd.ch\/de\/stories\/gemeinsam-gegen-brustkrebs\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.msd.ch\/de\/stories\/gemeinsam-gegen-brustkrebs\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.msd.ch\/de\/stories\/gemeinsam-gegen-brustkrebs\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Stories","item":"https:\/\/www.msd.ch\/de\/stories-archive\/"},{"@type":"ListItem","position":2,"name":"Gemeinsam gegen Brustkrebs\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0"}]},{"@type":"WebSite","@id":"https:\/\/www.msd.ch\/de\/#website","url":"https:\/\/www.msd.ch\/de\/","name":"msd.ch","description":"MSD erforscht und entwickelt Medikamente und Impfstoffe, die Leben retten und die Gesundheit von Patienten verbessern sollen. In der Schweiz setzen sich 1000 Mitarbeitende in Luzern und Z\u00fcrich daf\u00fcr ein.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.msd.ch\/de\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"}]}},"acf":[],"extended_data":{"featured_image":"https:\/\/www.msd.ch\/de\/wp-content\/uploads\/sites\/88\/2025\/04\/sponsoring-gv-award_181.jpg?w=1024","acf_fields":{"mco_page_tracking_data":"","page_text_direction_selection":"ltr","show_section":true,"related_content_section_heading":"Mehr \u00fcber uns","heading_level":"","story_one_selection":"select","related_content_item_one":{"ID":2759,"post_author":"974","post_date":"2026-03-31 21:02:02","post_date_gmt":"2026-03-31 19:02:02","post_content":"<!-- wp:acf\/hero-block {\"name\":\"acf\/hero-block\",\"data\":{\"mco_hero_block_tagline_text\":\"\",\"_mco_hero_block_tagline_text\":\"mco_hero_block_tagline_text\",\"mco_hero_block_ttle\":\"Klinische Studien von MSD in der Schweiz\",\"_mco_hero_block_ttle\":\"mco_hero_block_title\",\"mco_hero_block_description\":\"\u201cKlinische Studien sind der Schl\u00fcssel zu neuen Erkenntnissen in der Diagnostik und Therapie von Erkrankungen. Wir sind stolz, in der Schweiz dazu beizutragen.\\u0022\\r\\n\\r\\n\\u003cem\\u003eKlaudia Georgi, Sr. Director Clinical Research MSD Switzerland \\u0026amp; Serbia\\u003c\/em\\u003e\",\"_mco_hero_block_description\":\"mco_hero_block_description\",\"mco_hero_block_image_url\":2760,\"_mco_hero_block_image_url\":\"mco_hero_block_image_url\",\"mcc_hero_block_primary_image_alt\":\"\",\"_mcc_hero_block_primary_image_alt\":\"mcc_hero_block_primary_image_alt_text\",\"mco_hero_block_image_small_url\":\"\",\"_mco_hero_block_image_small_url\":\"mco_hero_block_image_small_url\",\"mcc_hero_block_secondary_image_alt\":\"\",\"_mcc_hero_block_secondary_image_alt\":\"mcc_hero_block_secondary_image_alt_text\",\"mco_hero_block_button_cta\":{\"title\":\"Grundwissen Klinische Studien\",\"url\":\"https:\/\/www.msd.ch\/de\/home\/research\/clinical-trials\/\",\"target\":\"\"},\"_mco_hero_block_button_cta\":\"mco_hero_block_button_cta\",\"mco_hero_block_button_cta_aria_label\":\"\",\"_mco_hero_block_button_cta_aria_label\":\"mco_hero_block_button_cta_aria_label\",\"hero_video_type\":\"youtube\",\"_hero_video_type\":\"hero_video_type\",\"youtube_video_url\":\"\",\"_youtube_video_url\":\"youtube_video\",\"video_accessible_name\":\"\",\"_video_accessible_name\":\"testimonial_video_accessible_name\",\"b2_hero_block_lazy_load_image\":\"0\",\"_b2_hero_block_lazy_load_image\":\"b2_hero_block_lazy_load_image_key\"},\"mode\":\"preview\"} \/-->\n\n<!-- wp:acf\/title-block {\"name\":\"acf\/title-block\",\"data\":{\"title\":\"Unsere Arbeit in Zahlen\",\"_title\":\"mco_title_block_title\",\"description\":\"\",\"_description\":\"mco_title_block_description\",\"content_label\":\"\",\"_content_label\":\"mco_title_block_content_label\",\"cta_one\":\"\",\"_cta_one\":\"mco_title_block_cta_one\",\"cta_two\":\"\",\"_cta_two\":\"mco_title_block_cta_two\",\"image\":\"\",\"_image\":\"mco_title_block_image\"},\"align\":\"center\",\"mode\":\"preview\",\"className\":\"pull-up-stats negative mb-2\"} \/-->\n\n<!-- wp:group -->\n<div class=\"wp-block-group\"><!-- wp:acf\/statistics-block {\"name\":\"acf\/statistics-block\",\"data\":{\"stat_statistic\":\"40\",\"_stat_statistic\":\"stat_block_statistic\",\"stat_caption\":\"\",\"_stat_caption\":\"stat_block_caption\",\"stat_description\":\"Laufende klinische Studien in der Schweiz\\r\\n(Stand 01\/2026)\\r\\n\",\"_stat_description\":\"stat_block_description\",\"stat_cta\":\"\",\"_stat_cta\":\"stat_block_cta_link\"},\"mode\":\"preview\"} \/-->\n\n<!-- wp:acf\/statistics-block {\"name\":\"acf\/statistics-block\",\"data\":{\"stat_statistic\":\"10\",\"_stat_statistic\":\"stat_block_statistic\",\"stat_caption\":\"\",\"_stat_caption\":\"stat_block_caption\",\"stat_description\":\"In der Schweiz zugelassene First-in-Class-Medikamente und Impfstoffe seit 2000\\r\\n(Stand 01\/2026)\",\"_stat_description\":\"stat_block_description\",\"stat_cta\":\"\",\"_stat_cta\":\"stat_block_cta_link\"},\"mode\":\"preview\"} \/-->\n\n<!-- wp:acf\/statistics-block {\"name\":\"acf\/statistics-block\",\"data\":{\"stat_statistic\":\"173\",\"_stat_statistic\":\"stat_block_statistic\",\"stat_caption\":\"\",\"_stat_caption\":\"stat_block_caption\",\"stat_description\":\"Millionen Schweizer Franken in die Forschung investiert, seit 2012 \\r\\n(Stand 01\/2026)\",\"_stat_description\":\"stat_block_description\",\"stat_cta\":\"\",\"_stat_cta\":\"stat_block_cta_link\"},\"mode\":\"preview\"} \/--><\/div>\n<!-- \/wp:group -->\n\n<!-- wp:acf\/content-block {\"name\":\"acf\/content-block\",\"data\":{\"maintain_image_aspect_ratio\":\"0\",\"_maintain_image_aspect_ratio\":\"content_block_maintain_image_aspect_ratio\",\"negative_style\":\"0\",\"_negative_style\":\"content_block_negative\",\"content_selection\":\"static\",\"_content_selection\":\"content_selction_method\",\"content_block_image\":13898,\"_content_block_image\":\"content_block_image\",\"content_block_heading\":\"Die klinische Forschung von MSD Schweiz wird in unserer Niederlassung in der R\u00f6sslimatt in Luzern koordiniert.\",\"_content_block_heading\":\"content_block_heading\",\"heading_level\":\"h3\",\"_heading_level\":\"content_block_heading_level\",\"content_block_body\":\"\",\"_content_block_body\":\"content_block_body\",\"content_block_cta\":{\"title\":\"Unsere Niederlassungen\",\"url\":\"https:\/\/www.msd.ch\/de\/home\/about-us\/sites\/\",\"target\":\"_blank\"},\"_content_block_cta\":\"content_block_cta\",\"content_block_aria_label\":\"\",\"_content_block_aria_label\":\"content_block_aria_label\",\"content_block_cta_button_style\":\"\",\"_content_block_cta_button_style\":\"content_block_cta_button_style_cf4f3fd32dc26ec4ba7a6c14e51289c8\",\"content_block_optional_cta\":\"\",\"_content_block_optional_cta\":\"content_block_optional_cta\",\"content_block_optional_cta_aria_label\":\"\",\"_content_block_optional_cta_aria_label\":\"content_block_optional_cta_aria_label\",\"content_block_optional_cta_button_style\":\"\",\"_content_block_optional_cta_button_style\":\"content_block_optional_cta_button_style_d7b3517ac72218a3fb8daa4bc7def7a4\",\"content_block_optional_tag\":\"\",\"_content_block_optional_tag\":\"content_block_optional_tag\",\"content_block_video\":\"\",\"_content_block_video\":\"content_block_video\",\"content_media_position\":\"left\",\"_content_media_position\":\"content_media_position\",\"brightcove_account_id\":\"\",\"_brightcove_account_id\":\"bright_cove_account_id\",\"content_block_video_accessible_name\":\"\",\"_content_block_video_accessible_name\":\"content_block_video_accessible_name\",\"content_block_play_button_accessible_name\":\"\",\"_content_block_play_button_accessible_name\":\"content_block_play_button_accessible_name\",\"content_block_popup_accessible_name\":\"\",\"_content_block_popup_accessible_name\":\"content_block_popup_accessible_name\",\"content_block_popup_close_button_accessible_name\":\"\",\"_content_block_popup_close_button_accessible_name\":\"content_block_popup_close_button_accessible_name\"},\"mode\":\"edit\"} \/-->\n\n<!-- wp:heading {\"textAlign\":\"center\",\"level\":1} -->\n<h1 class=\"wp-block-heading has-text-align-center\">Das klinische Studienprogramm von MSD in der Schweiz (Stand 01\/2026)<\/h1>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph {\"align\":\"center\"} -->\n<p class=\"has-text-align-center\">(ver\u00f6ffentlicht auf <a href=\"http:\/\/www.clinicaltrials.gov\">www.clinicaltrials.gov<\/a>)<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:columns -->\n<div class=\"wp-block-columns\"><!-- wp:column -->\n<div class=\"wp-block-column\"><!-- wp:image {\"id\":13485,\"sizeSlug\":\"full\",\"linkDestination\":\"none\",\"className\":\"mb-2\"} -->\n<figure class=\"wp-block-image size-full mb-2\"><img src=\"https:\/\/www.msd.ch\/de\/wp-content\/uploads\/sites\/88\/2026\/01\/2026-01-MSD-Karte-Klinische-Studienprogramm-Schweiz.png\" alt=\"Karte: Standorte Klinische Studie MSD Schweiz (Stand 01\/2026)\" class=\"wp-image-13485\"\/><\/figure>\n<!-- \/wp:image --><\/div>\n<!-- \/wp:column --><\/div>\n<!-- \/wp:columns -->\n\n<!-- wp:acf\/b6-accordion-list {\"name\":\"acf\/b6-accordion-list\",\"data\":{\"mco_b6_accordion_list_tagline\":\"\",\"_mco_b6_accordion_list_tagline\":\"mco_b6_accordion_list_tagline_6947uhf9ywhuj\",\"mco_b6_accordion_list_title\":\"Im Bereich Allgemeinmedizin\",\"_mco_b6_accordion_list_title\":\"mco_b6_accordion_list_title_6947uhf9ywhuj\",\"mco_b6_accordion_type\":\"multiple\",\"_mco_b6_accordion_type\":\"mco_b6_accordion_type_6947uhf9ywhuj\",\"mco_b6_accordion_list_collapse_button\":\"1\",\"_mco_b6_accordion_list_collapse_button\":\"mco_b6_accordion_expand_all_6947uhf9ywhuj\",\"mco_b6_accordion_expand_all\":\"Alle aufklappen\",\"_mco_b6_accordion_expand_all\":\"mco_b6_accordion_expand_all\",\"mco_b6_accordion_close_all\":\"Alle schliessen\",\"_mco_b6_accordion_close_all\":\"mco_b6_accordion_close\",\"mco_b6_accordion_add_faq\":\"1\",\"_mco_b6_accordion_add_faq\":\"mco_b6_accordion_add_faq\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_summary\":\"Lungenkrankheit\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_summary\":\"mco_b6_accordion_list_row_summary_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_heading\":\"h5\",\"_mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_heading\":\"mcc_b6_accordion_list_custom_headings\",\"mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_anchor_id\":\"\",\"_mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_anchor_id\":\"mcc_b6_accordion_list_custom_id\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_details\":\"\\u003cstrong\\u003eMK-5475-013 \u2013 recruitment closed\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 2a Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-5475 in Adults With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease\\r\\n\\r\\nStudy centers: St. Gallen, Zurich, Basel\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003cstrong\\u003eMK-7962-038 \u2013 Study in start-up\\u003c\/strong\\u003e\\r\\n\\r\\nAn Open-label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH\\r\\n\\r\\nStudy center: Zurich\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_details\":\"mco_b6_accordion_list_row_details_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_image\":\"\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_image\":\"mco_b6_accordion_list_row_image_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_open\":\"0\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_open\":\"mco_b6_accordion_list_row_open_6947uhf9ywhuj\",\"mco_b6_accordion_list_row\":1,\"_mco_b6_accordion_list_row\":\"mco_b6_accordion_list_row_6947uhf9ywhuj\"},\"mode\":\"edit\"} \/-->\n\n<!-- wp:acf\/b6-accordion-list {\"name\":\"acf\/b6-accordion-list\",\"data\":{\"mco_b6_accordion_list_tagline\":\"\",\"_mco_b6_accordion_list_tagline\":\"mco_b6_accordion_list_tagline_6947uhf9ywhuj\",\"mco_b6_accordion_list_title\":\"Im Bereich Immunologie\",\"_mco_b6_accordion_list_title\":\"mco_b6_accordion_list_title_6947uhf9ywhuj\",\"mco_b6_accordion_type\":\"multiple\",\"_mco_b6_accordion_type\":\"mco_b6_accordion_type_6947uhf9ywhuj\",\"mco_b6_accordion_list_collapse_button\":\"1\",\"_mco_b6_accordion_list_collapse_button\":\"mco_b6_accordion_expand_all_6947uhf9ywhuj\",\"mco_b6_accordion_expand_all\":\"Alle aufklappen\",\"_mco_b6_accordion_expand_all\":\"mco_b6_accordion_expand_all\",\"mco_b6_accordion_close_all\":\"Alle schliessen\",\"_mco_b6_accordion_close_all\":\"mco_b6_accordion_close\",\"mco_b6_accordion_add_faq\":\"1\",\"_mco_b6_accordion_add_faq\":\"mco_b6_accordion_add_faq\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_summary\":\"Darmkrankheit\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_summary\":\"mco_b6_accordion_list_row_summary_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_heading\":\"h5\",\"_mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_heading\":\"mcc_b6_accordion_list_custom_headings\",\"mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_anchor_id\":\"\",\"_mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_anchor_id\":\"mcc_b6_accordion_list_custom_id\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_details\":\"\\u003cstrong\\u003eMK-7240-001 \u2013 recruitment closed\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 3, Randomized, Double-Blind, Placebo-Controlled Program to Evaluate the Efficacy and Safety of MK-7240 in Participants with Moderately to Severely Active Ulcerative Colitis\\r\\n\\r\\nStudy centers: Bern, St. Gallen, Zurich\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003cstrong\\u003eMK-7240-008 \u2013 recruitment open\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 3, Randomized, Double-Blind, Placebo-Controlled Program to Evaluate the Efficacy and Safety of MK-7240 in Participants with Moderately to Severely Active Crohn\u2019s Disease\\r\\n\\r\\nStudy centers: Basel, Bern, St. Gallen, Zurich\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_details\":\"mco_b6_accordion_list_row_details_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_image\":\"\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_image\":\"mco_b6_accordion_list_row_image_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_open\":\"0\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_open\":\"mco_b6_accordion_list_row_open_6947uhf9ywhuj\",\"mco_b6_accordion_list_row\":1,\"_mco_b6_accordion_list_row\":\"mco_b6_accordion_list_row_6947uhf9ywhuj\"},\"mode\":\"edit\"} \/-->\n\n<!-- wp:acf\/b6-accordion-list {\"name\":\"acf\/b6-accordion-list\",\"data\":{\"mco_b6_accordion_list_tagline\":\"\",\"_mco_b6_accordion_list_tagline\":\"mco_b6_accordion_list_tagline_6947uhf9ywhuj\",\"mco_b6_accordion_list_title\":\"Im Bereich Infektiologie\",\"_mco_b6_accordion_list_title\":\"mco_b6_accordion_list_title_6947uhf9ywhuj\",\"mco_b6_accordion_type\":\"multiple\",\"_mco_b6_accordion_type\":\"mco_b6_accordion_type_6947uhf9ywhuj\",\"mco_b6_accordion_list_collapse_button\":\"1\",\"_mco_b6_accordion_list_collapse_button\":\"mco_b6_accordion_expand_all_6947uhf9ywhuj\",\"mco_b6_accordion_expand_all\":\"Alle aufklappen\",\"_mco_b6_accordion_expand_all\":\"mco_b6_accordion_expand_all\",\"mco_b6_accordion_close_all\":\"Alle schliessen\",\"_mco_b6_accordion_close_all\":\"mco_b6_accordion_close\",\"mco_b6_accordion_add_faq\":\"1\",\"_mco_b6_accordion_add_faq\":\"mco_b6_accordion_add_faq\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_summary\":\"HIV\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_summary\":\"mco_b6_accordion_list_row_summary_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_heading\":\"h5\",\"_mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_heading\":\"mcc_b6_accordion_list_custom_headings\",\"mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_anchor_id\":\"\",\"_mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_anchor_id\":\"mcc_b6_accordion_list_custom_id\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_details\":\"\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\r\\n\\u003cstrong\\u003eMK-8527-011 \u2013 recruitment open\\u003c\/strong\\u003e\\r\\n\\r\\nPhase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis\\r\\n\\r\\nStudy centers: Basel, Bern, Zurich\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003cstrong\\u003eMK-8591A-051 \u2013 recruitment closed\\u003c\/strong\\u003e\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\nA Phase 3, Randomized, Active-Controlled, Open-Label Clinical Study to Evaluate a Switch to Doravirine\/Islatravir (DOR\/ISL 100 mg\/0.25 mg) Once-Daily in Participants With HIV-1 Who Are Virologically Suppressed on Antiretroviral Therapy\\r\\n\\r\\nStudy centers: Basel, Bern, Geneva, Lausanne, Lugano, Zurich\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\n\\u003cstrong\\u003eMK-8591A-053 \u2013 recruitment closed\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Doravirine\/Islatravir (DOR\/ISL 100 mg\/0.25 mg) Once-Daily in HIV-1 Infected Treatment-Na\u00efve Participants\\r\\n\\r\\nStudy centers: Basel, Geneva\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\r\\n\\u003cstrong\\u003eMK-8591A-054 \u2013 recruitment closed\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 3 Open-label Clinical Study of Doravirine\/Islatravir (DOR\/ISL [100 mg\/0.25 mg]) Once Daily for the Treatment of HIV-1 Infection in Participants Who Previously Received DOR\/ISL (100 mg\/0.75 mg) QD in a Phase 3 Clinical Study\\r\\n\\r\\nStudy centers: Basel, Bern, Geneva, St. Gallen, Lugano, Zurich\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\n\\u003cstrong\\u003eMK-8591B-060 \u2013 recruitment closed\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 2b, Randomized, Active-Controlled, Open-Label Clinical Study to Evaluate a Switch to Islatravir (ISL) and Ulonivirine (ULO) Once-Weekly in Adults with HIV-1 Virologically Suppressed on Bictegravir\/Emtricitabine\/Tenofovir Alafenamide (BIC\/FTC\/TAF) Once-Daily\\r\\n\\r\\nStudy centers: Basel, Bern, Geneva, Lugano\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_details\":\"mco_b6_accordion_list_row_details_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_image\":\"\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_image\":\"mco_b6_accordion_list_row_image_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_open\":\"0\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_open\":\"mco_b6_accordion_list_row_open_6947uhf9ywhuj\",\"mco_b6_accordion_list_row\":1,\"_mco_b6_accordion_list_row\":\"mco_b6_accordion_list_row_6947uhf9ywhuj\"},\"mode\":\"edit\",\"className\":\"mt-2\"} \/-->\n\n<!-- wp:acf\/b6-accordion-list {\"name\":\"acf\/b6-accordion-list\",\"data\":{\"mco_b6_accordion_list_tagline\":\"\",\"_mco_b6_accordion_list_tagline\":\"mco_b6_accordion_list_tagline_6947uhf9ywhuj\",\"mco_b6_accordion_list_title\":\"Im Bereich Onkologie\",\"_mco_b6_accordion_list_title\":\"mco_b6_accordion_list_title_6947uhf9ywhuj\",\"mco_b6_accordion_type\":\"multiple\",\"_mco_b6_accordion_type\":\"mco_b6_accordion_type_6947uhf9ywhuj\",\"mco_b6_accordion_list_collapse_button\":\"1\",\"_mco_b6_accordion_list_collapse_button\":\"mco_b6_accordion_expand_all_6947uhf9ywhuj\",\"mco_b6_accordion_expand_all\":\"Alle aufklappen\",\"_mco_b6_accordion_expand_all\":\"mco_b6_accordion_expand_all\",\"mco_b6_accordion_close_all\":\"Alle schliessen\",\"_mco_b6_accordion_close_all\":\"mco_b6_accordion_close\",\"mco_b6_accordion_add_faq\":\"1\",\"_mco_b6_accordion_add_faq\":\"mco_b6_accordion_add_faq\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_summary\":\"Blasenkrebs\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_summary\":\"mco_b6_accordion_list_row_summary_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_heading\":\"h5\",\"_mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_heading\":\"mcc_b6_accordion_list_custom_headings\",\"mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_anchor_id\":\"\",\"_mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_anchor_id\":\"mcc_b6_accordion_list_custom_id\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_details\":\"\\u003cp class=\\u0022col l9 m9 s12\\u0022\\u003e\\u003cstrong\\u003eMK-3475-676\/KEYNOTE-676 - recruitment closed\\u003c\/strong\\u003e\\u003c\/p\\u003e\\r\\n\\u003cp class=\\u0022col l9 m9 s12\\u0022\\u003eA Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Bacillus Calmette-Guerin (BCG) in Participants with High-risk Non-muscle Invasive Bladder Cancer (HRNMIBC) that is Persistent or Recurrent Following BCG Induction (KEYNOTE-676)\\u003c\/p\\u003e\\r\\n\\u003cp class=\\u0022col l2 m2 offset-l1 offset-m1 s12\\u0022\\u003eStudy centers: Basel, Geneva, Zurich\\u003c\/p\\u003e\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_details\":\"mco_b6_accordion_list_row_details_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_image\":\"\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_image\":\"mco_b6_accordion_list_row_image_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_open\":\"0\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_open\":\"mco_b6_accordion_list_row_open_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_1_mco_b6_accordion_list_row_summary\":\"Blutkrebs (H\u00e4matologische Malignome)\",\"_mco_b6_accordion_list_row_1_mco_b6_accordion_list_row_summary\":\"mco_b6_accordion_list_row_summary_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_1_mcc_b6_accordion_custom_heading\":\"h5\",\"_mco_b6_accordion_list_row_1_mcc_b6_accordion_custom_heading\":\"mcc_b6_accordion_list_custom_headings\",\"mco_b6_accordion_list_row_1_mcc_b6_accordion_custom_anchor_id\":\"\",\"_mco_b6_accordion_list_row_1_mcc_b6_accordion_custom_anchor_id\":\"mcc_b6_accordion_list_custom_id\",\"mco_b6_accordion_list_row_1_mco_b6_accordion_list_row_details\":\"\\u003cstrong\\u003eMK-1026-003 - recruitment open\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants with Hematologic Malignancies\\r\\n\\r\\nStudy centers: Bellinzona, Bern\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003cstrong\\u003eMK-2140-010 \u2013 recruitment open\\u003c\/strong\\u003e\\r\\n\\r\\nA Randomized, Open-Label, Multicenter, Phase 3 Study of Zilovertamab Vedotin (MK-2140) in Combination With R-CHP Versus R-CHOP in Participants With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) (waveLINE-010)\\r\\n\\r\\nStudy centers: Baden, Bellinzona, St. Gallen\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003cstrong\\u003eMK-4280A-008 \u2013 recruitment closed\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 3 Randomized Clinical Study of MK-4280A (coformulated favezelimab [MK-4280] plus pembrolizumab [MK-3475]) Versus Physician\u2019s Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (KEYFORM-008)\\r\\n\\r\\nStudy centers: Bellinzona\",\"_mco_b6_accordion_list_row_1_mco_b6_accordion_list_row_details\":\"mco_b6_accordion_list_row_details_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_1_mco_b6_accordion_list_row_image\":\"\",\"_mco_b6_accordion_list_row_1_mco_b6_accordion_list_row_image\":\"mco_b6_accordion_list_row_image_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_1_mco_b6_accordion_list_row_open\":\"0\",\"_mco_b6_accordion_list_row_1_mco_b6_accordion_list_row_open\":\"mco_b6_accordion_list_row_open_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_2_mco_b6_accordion_list_row_summary\":\"Brustkrebs\",\"_mco_b6_accordion_list_row_2_mco_b6_accordion_list_row_summary\":\"mco_b6_accordion_list_row_summary_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_2_mcc_b6_accordion_custom_heading\":\"h5\",\"_mco_b6_accordion_list_row_2_mcc_b6_accordion_custom_heading\":\"mcc_b6_accordion_list_custom_headings\",\"mco_b6_accordion_list_row_2_mcc_b6_accordion_custom_anchor_id\":\"\",\"_mco_b6_accordion_list_row_2_mcc_b6_accordion_custom_anchor_id\":\"mcc_b6_accordion_list_custom_id\",\"mco_b6_accordion_list_row_2_mco_b6_accordion_list_row_details\":\"\\u003cstrong\\u003eMK-2870-010 \u2013 recruitment open\\u003c\/strong\\u003e\\r\\n\\r\\nAn Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination with Pembrolizumab Versus Treatment of Physician`s Choice in Participants with HR+\/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer\\r\\n\\r\\nStudy centers: Basel, Thun, Zurich\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003cstrong\\u003eMK-2870-012 \u2013 recruitment open\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination with Pembrolizumab (MK-3475) Versus Treatment of Physician\u2019s Choice in Participants With Triple Negative Breast Cancer (TNBC) Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response (pCR) At Surgery\\r\\n\\r\\nStudy centers: Chur, Fribourg, Geneva, Thun, Zurich\",\"_mco_b6_accordion_list_row_2_mco_b6_accordion_list_row_details\":\"mco_b6_accordion_list_row_details_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_2_mco_b6_accordion_list_row_image\":\"\",\"_mco_b6_accordion_list_row_2_mco_b6_accordion_list_row_image\":\"mco_b6_accordion_list_row_image_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_2_mco_b6_accordion_list_row_open\":\"0\",\"_mco_b6_accordion_list_row_2_mco_b6_accordion_list_row_open\":\"mco_b6_accordion_list_row_open_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_3_mco_b6_accordion_list_row_summary\":\"Gyn\u00e4kologische Krebserkrankungen\",\"_mco_b6_accordion_list_row_3_mco_b6_accordion_list_row_summary\":\"mco_b6_accordion_list_row_summary_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_3_mcc_b6_accordion_custom_heading\":\"h5\",\"_mco_b6_accordion_list_row_3_mcc_b6_accordion_custom_heading\":\"mcc_b6_accordion_list_custom_headings\",\"mco_b6_accordion_list_row_3_mcc_b6_accordion_custom_anchor_id\":\"\",\"_mco_b6_accordion_list_row_3_mcc_b6_accordion_custom_anchor_id\":\"mcc_b6_accordion_list_custom_id\",\"mco_b6_accordion_list_row_3_mco_b6_accordion_list_row_details\":\"\\u003cstrong\\u003eMK-2870-005 \u2013 recruitment closed\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician\u2019s Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Immunotherapy\\r\\n\\r\\nStudy centers: Bern, Bellinzona, Chur, Basel\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003cstrong\\u003eMK-2870-020 \u2013 recruitment closed\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 3 Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician\u2019s Choice as Second-line Treatment for Participants with Recurrent or Metastatic Cervical Cancer\\r\\n\\r\\nStudy centers: Basel, Bern\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003cstrong\\u003eMK-2870-021 \u2013 Study in start-up\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 3, Randomized, Open-label, Multicenter Study of Sacituzumab Tirumotecan (sac-TMT, MK-2870) Maintenance Treatment With or Without Bevacizumab Versus Standard of Care in Participants With Newly Diagnosed Advanced HRD-Negative Ovarian Cancer Following First-line Platinum-based Chemotherapy (TroFuse-021\/ENGOTov85\/GOG-3102)\\r\\n\\r\\nStudy centers: Bern, Bellinzona, Chur, Geneva, Winterthur\",\"_mco_b6_accordion_list_row_3_mco_b6_accordion_list_row_details\":\"mco_b6_accordion_list_row_details_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_3_mco_b6_accordion_list_row_image\":\"\",\"_mco_b6_accordion_list_row_3_mco_b6_accordion_list_row_image\":\"mco_b6_accordion_list_row_image_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_3_mco_b6_accordion_list_row_open\":\"0\",\"_mco_b6_accordion_list_row_3_mco_b6_accordion_list_row_open\":\"mco_b6_accordion_list_row_open_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_4_mco_b6_accordion_list_row_summary\":\"Kopf- und Halskrebs\",\"_mco_b6_accordion_list_row_4_mco_b6_accordion_list_row_summary\":\"mco_b6_accordion_list_row_summary_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_4_mcc_b6_accordion_custom_heading\":\"h5\",\"_mco_b6_accordion_list_row_4_mcc_b6_accordion_custom_heading\":\"mcc_b6_accordion_list_custom_headings\",\"mco_b6_accordion_list_row_4_mcc_b6_accordion_custom_anchor_id\":\"\",\"_mco_b6_accordion_list_row_4_mcc_b6_accordion_custom_anchor_id\":\"mcc_b6_accordion_list_custom_id\",\"mco_b6_accordion_list_row_4_mco_b6_accordion_list_row_details\":\"\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\u003cstrong\\u003eMK-3475-689\/KEYNOTE-689 \u2013 recruitment closed\\u003c\/strong\\u003e\\u003c\/div\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\r\\nA Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)\\r\\n\\r\\nStudy center: Geneva\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\",\"_mco_b6_accordion_list_row_4_mco_b6_accordion_list_row_details\":\"mco_b6_accordion_list_row_details_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_4_mco_b6_accordion_list_row_image\":\"\",\"_mco_b6_accordion_list_row_4_mco_b6_accordion_list_row_image\":\"mco_b6_accordion_list_row_image_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_4_mco_b6_accordion_list_row_open\":\"0\",\"_mco_b6_accordion_list_row_4_mco_b6_accordion_list_row_open\":\"mco_b6_accordion_list_row_open_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_5_mco_b6_accordion_list_row_summary\":\"Lungenkrebs\",\"_mco_b6_accordion_list_row_5_mco_b6_accordion_list_row_summary\":\"mco_b6_accordion_list_row_summary_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_5_mcc_b6_accordion_custom_heading\":\"h5\",\"_mco_b6_accordion_list_row_5_mcc_b6_accordion_custom_heading\":\"mcc_b6_accordion_list_custom_headings\",\"mco_b6_accordion_list_row_5_mcc_b6_accordion_custom_anchor_id\":\"\",\"_mco_b6_accordion_list_row_5_mcc_b6_accordion_custom_anchor_id\":\"mcc_b6_accordion_list_custom_id\",\"mco_b6_accordion_list_row_5_mco_b6_accordion_list_row_details\":\"\\u003cstrong\\u003eMK-1084-007 \u2013 Study in start-up\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084 in Combination With Subcutaneous Pembrolizumab and Berahyaluronidase alfa (MK-3475A) Versus MK-3475A in Combination With Pemetrexed\/Platinum (Carboplatin or Cisplatin) Chemotherapy as First-line Treatment of Participants With KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous NSCLC (KANDLELIT-007)\\r\\n\\r\\nStudy centers: Fribourg, Zurich\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003cstrong\\u003eMK-2870-019 \u2013 \\u003cspan class=\\u0022gray_text\\u0022\\u003erecruitment open\\u003c\/span\\u003e\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 3 Randomized Open-label Study of Adjuvant Pembrolizumab with or without MK-2870 in Resectable Stages II-IIIB (N2) NSCLC for participants not achieving pCR after Receiving Neoadjuvant Pembrolizumab with Platinum-based Doublet Chemotherapy Followed by Surgery\\r\\n\\r\\nStudy centers: Lausanne, Fribourg, Frauenfeld, Chur\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cp class=\\u0022col l9 m9 s12\\u0022\\u003e\\u003cstrong\\u003eMK-3475-091\/KEYNOTE-091 -\u00a0\\u003cspan class=\\u0022gray_text\\u0022\\u003eoutsourced - recruitment closed\\u003c\/span\\u003e\\u003c\/strong\\u003e\\u003c\/p\\u003e\\r\\n\\u003cp class=\\u0022col l9 m9 s12\\u0022\\u003eA randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (PEARLS)\\u003c\/p\\u003e\\r\\n\\u003cp class=\\u0022col l2 m2 offset-l1 offset-m1 s12\\u0022\\u003eStudy centers: Basel, Bellinzona, Bern, Chur, Geneva, Lausanne, Lucerne, St. Gallen, Winterthur, Zurich\\u003c\/p\\u003e\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\r\\n\\u003cstrong\\u003eMK-3475-B98 - recruitment closed\\u003c\/strong\\u003e\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cp class=\\u0022col l9 m9 s12\\u0022\\u003eA Phase 1b\/2 Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination with Investigational Agents for the Treatment of Participants With PD-1\/L1-refactory Extensive Stage Small Cell Lung Cancer in Need of Second-Line Therapy\\u003c\/p\\u003e\\r\\n\\u003cp class=\\u0022col l2 m2 offset-l1 offset-m1 s12\\u0022\\u003eStudy center: St. Gallen\\u003c\/p\\u003e\\r\\n\\r\\n\\u003c\/div\\u003e\",\"_mco_b6_accordion_list_row_5_mco_b6_accordion_list_row_details\":\"mco_b6_accordion_list_row_details_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_5_mco_b6_accordion_list_row_image\":\"\",\"_mco_b6_accordion_list_row_5_mco_b6_accordion_list_row_image\":\"mco_b6_accordion_list_row_image_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_5_mco_b6_accordion_list_row_open\":\"0\",\"_mco_b6_accordion_list_row_5_mco_b6_accordion_list_row_open\":\"mco_b6_accordion_list_row_open_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_6_mco_b6_accordion_list_row_summary\":\"Magenkrebs\",\"_mco_b6_accordion_list_row_6_mco_b6_accordion_list_row_summary\":\"mco_b6_accordion_list_row_summary_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_6_mcc_b6_accordion_custom_heading\":\"h5\",\"_mco_b6_accordion_list_row_6_mcc_b6_accordion_custom_heading\":\"mcc_b6_accordion_list_custom_headings\",\"mco_b6_accordion_list_row_6_mcc_b6_accordion_custom_anchor_id\":\"\",\"_mco_b6_accordion_list_row_6_mcc_b6_accordion_custom_anchor_id\":\"mcc_b6_accordion_list_custom_id\",\"mco_b6_accordion_list_row_6_mco_b6_accordion_list_row_details\":\"\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\r\\n\\u003cstrong\\u003eMK-1022-011 \u2013 recruitment open\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 1\/2 Study to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Gastrointestinal Cancers\\r\\n\\r\\nStudy centers: Geneva, Zurich\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cp class=\\u0022col l2 m2 offset-l1 offset-m1 s12\\u0022\\u003e\\u003cstrong\\u003eMK-5909-005 \u2013 recruitment open\\u003c\/strong\\u003e\\u003c\/p\\u003e\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\nA Phase 2 Nonrandomized, Open-label, Multisite Study to Evaluate the Safety and Efficacy of Raludotatug Deruxtecan in Participants With Gastrointestinal Cancers\\r\\n\\r\\nStudy centers: Basel, Zurich, Geneva\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003cstrong\\u003eMK-9999-U02A \u2013 recruitment open\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 1\/2 Substudy of the MK-9999-U02 Master Protocol to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers\\r\\n\\r\\nStudy centers: Bellinzona, Geneva\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\",\"_mco_b6_accordion_list_row_6_mco_b6_accordion_list_row_details\":\"mco_b6_accordion_list_row_details_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_6_mco_b6_accordion_list_row_image\":\"\",\"_mco_b6_accordion_list_row_6_mco_b6_accordion_list_row_image\":\"mco_b6_accordion_list_row_image_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_6_mco_b6_accordion_list_row_open\":\"0\",\"_mco_b6_accordion_list_row_6_mco_b6_accordion_list_row_open\":\"mco_b6_accordion_list_row_open_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_7_mco_b6_accordion_list_row_summary\":\"Melanom (Schwarzer Hautkrebs)\",\"_mco_b6_accordion_list_row_7_mco_b6_accordion_list_row_summary\":\"mco_b6_accordion_list_row_summary_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_7_mcc_b6_accordion_custom_heading\":\"h5\",\"_mco_b6_accordion_list_row_7_mcc_b6_accordion_custom_heading\":\"mcc_b6_accordion_list_custom_headings\",\"mco_b6_accordion_list_row_7_mcc_b6_accordion_custom_anchor_id\":\"\",\"_mco_b6_accordion_list_row_7_mcc_b6_accordion_custom_anchor_id\":\"mcc_b6_accordion_list_custom_id\",\"mco_b6_accordion_list_row_7_mco_b6_accordion_list_row_details\":\"\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\u003cstrong\\u003eMK-3475-054 \/ KEYNOTE-054 - \\u003cspan class=\\u0022gray_text\\u0022\\u003eoutsourced - recruitment closed\\u003c\/span\\u003e\\u003c\/strong\\u003e\\u003c\/div\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cp class=\\u0022col l9 m9 s12\\u0022\\u003eAdjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, double-blind Phase 3 trial of the EORTC Melanoma Group\\u003c\/p\\u003e\\r\\n\\u003cp class=\\u0022col l2 m2 offset-l1 offset-m1 s12\\u0022\\u003eStudy centers: Geneva, Zurich\\u003c\/p\\u003e\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cp class=\\u0022col l9 m9 s12\\u0022\\u003e\\u003cstrong\\u003eMK-3475-716\/KEYNOTE-716 -\u00a0\\u003cspan class=\\u0022green_text\\u0022\\u003erecruitment closed\\u003c\/span\\u003e\\u003c\/strong\\u003e\\u003c\/p\\u003e\\r\\n\\u003cp class=\\u0022col l9 m9 s12\\u0022\\u003eAdjuvant Therapy with Pembrolizumab Versus Placebo in Resected High-risk Stage II Melanoma: A Randomized, Double-blind Phase 3 Study\\u003c\/p\\u003e\\r\\n\\u003cp class=\\u0022col l2 m2 offset-l1 offset-m1 s12\\u0022\\u003eStudy centers: Bellinzona, Bern, Chur, Geneva, Lausanne, Sion, St. Gallen, Zurich\\u003c\/p\\u003e\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\",\"_mco_b6_accordion_list_row_7_mco_b6_accordion_list_row_details\":\"mco_b6_accordion_list_row_details_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_7_mco_b6_accordion_list_row_image\":\"\",\"_mco_b6_accordion_list_row_7_mco_b6_accordion_list_row_image\":\"mco_b6_accordion_list_row_image_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_7_mco_b6_accordion_list_row_open\":\"0\",\"_mco_b6_accordion_list_row_7_mco_b6_accordion_list_row_open\":\"mco_b6_accordion_list_row_open_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_8_mco_b6_accordion_list_row_summary\":\"Nierenkrebs (Nierenzellkarzinom)\",\"_mco_b6_accordion_list_row_8_mco_b6_accordion_list_row_summary\":\"mco_b6_accordion_list_row_summary_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_8_mcc_b6_accordion_custom_heading\":\"h5\",\"_mco_b6_accordion_list_row_8_mcc_b6_accordion_custom_heading\":\"mcc_b6_accordion_list_custom_headings\",\"mco_b6_accordion_list_row_8_mcc_b6_accordion_custom_anchor_id\":\"\",\"_mco_b6_accordion_list_row_8_mcc_b6_accordion_custom_anchor_id\":\"mcc_b6_accordion_list_custom_id\",\"mco_b6_accordion_list_row_8_mco_b6_accordion_list_row_details\":\"\\u003cp class=\\u0022col l9 m9 s12\\u0022\\u003e\\u003cstrong\\u003eMK-6482-011 - recruitment closed\\u003c\/strong\\u003e\\u003c\/p\\u003e\\r\\n\\u003cp class=\\u0022col l9 m9 s12\\u0022\\u003eAn Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1\/L1 Therapy\\u003c\/p\\u003e\\r\\n\\u003cp class=\\u0022col l2 m2 offset-l1 offset-m1 s12\\u0022\\u003eStudy centers: Bellinzona, Chur, Geneva, Zurich\\u003c\/p\\u003e\",\"_mco_b6_accordion_list_row_8_mco_b6_accordion_list_row_details\":\"mco_b6_accordion_list_row_details_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_8_mco_b6_accordion_list_row_image\":\"\",\"_mco_b6_accordion_list_row_8_mco_b6_accordion_list_row_image\":\"mco_b6_accordion_list_row_image_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_8_mco_b6_accordion_list_row_open\":\"0\",\"_mco_b6_accordion_list_row_8_mco_b6_accordion_list_row_open\":\"mco_b6_accordion_list_row_open_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_9_mco_b6_accordion_list_row_summary\":\"Prostatakrebs\",\"_mco_b6_accordion_list_row_9_mco_b6_accordion_list_row_summary\":\"mco_b6_accordion_list_row_summary_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_9_mcc_b6_accordion_custom_heading\":\"h5\",\"_mco_b6_accordion_list_row_9_mcc_b6_accordion_custom_heading\":\"mcc_b6_accordion_list_custom_headings\",\"mco_b6_accordion_list_row_9_mcc_b6_accordion_custom_anchor_id\":\"\",\"_mco_b6_accordion_list_row_9_mcc_b6_accordion_custom_anchor_id\":\"mcc_b6_accordion_list_custom_id\",\"mco_b6_accordion_list_row_9_mco_b6_accordion_list_row_details\":\"\\u003cstrong\\u003eMK-2400-001 \u2013 recruitment open\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 3, Open-label Study of Ifinatamab Deruxtecan Versus Docetaxel in Participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC)\\r\\n\\r\\nStudy centers: Aarau, Basel, Fribourg, Geneva, Zurich\",\"_mco_b6_accordion_list_row_9_mco_b6_accordion_list_row_details\":\"mco_b6_accordion_list_row_details_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_9_mco_b6_accordion_list_row_image\":\"\",\"_mco_b6_accordion_list_row_9_mco_b6_accordion_list_row_image\":\"mco_b6_accordion_list_row_image_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_9_mco_b6_accordion_list_row_open\":\"0\",\"_mco_b6_accordion_list_row_9_mco_b6_accordion_list_row_open\":\"mco_b6_accordion_list_row_open_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_10_mco_b6_accordion_list_row_summary\":\"Solide Tumore\",\"_mco_b6_accordion_list_row_10_mco_b6_accordion_list_row_summary\":\"mco_b6_accordion_list_row_summary_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_10_mcc_b6_accordion_custom_heading\":\"h5\",\"_mco_b6_accordion_list_row_10_mcc_b6_accordion_custom_heading\":\"mcc_b6_accordion_list_custom_headings\",\"mco_b6_accordion_list_row_10_mcc_b6_accordion_custom_anchor_id\":\"\",\"_mco_b6_accordion_list_row_10_mcc_b6_accordion_custom_anchor_id\":\"mcc_b6_accordion_list_custom_id\",\"mco_b6_accordion_list_row_10_mco_b6_accordion_list_row_details\":\"\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\r\\n\\u003cstrong\\u003eMK-0472-001 \u2013 recruitment open\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 1\/1b Open-label, Multicenter Clinical Study of MK-0472 as Monotherapy and Combination Therapy in Participants with Advanced\/Metastatic Solid Tumors.\\r\\n\\r\\nStudy centers: Geneva, Bellinzona, St. Gallen\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\u003cp class=\\u0022col l9 m9 s12\\u0022\\u003e\\u003cstrong\\u003eMK-1084-001 - recruitment open\\u003c\/strong\\u003e\\u003c\/p\\u003e\\r\\nA Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and in Combination with Pembrolizumab in Subjects with KRASG12C Mutant Advanced Solid Tumors\\r\\n\\r\\nStudy centers: Bellinzona, St. Gallen\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\\r\\n\\u0026nbsp;\\r\\n\\u003cp class=\\u0022col l9 m9 s12\\u0022\\u003e\\u003cstrong\\u003eMK-3475-587\/KEYNOTE-587 - recruitment closed\\u003c\/strong\\u003e\\u003c\/p\\u003e\\r\\n\\u003cp class=\\u0022col l9 m9 s12\\u0022\\u003eLong-term Safety and Efficacy Extension Study for Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study\\u003c\/p\\u003e\\r\\n\\u003cp class=\\u0022col l2 m2 offset-l1 offset-m1 s12\\u0022\\u003eStudy center: Basel, Geneva, Zurich\\u003c\/p\\u003e\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003cstrong\\u003eMK-4884-001 \u2013 Study in start-up\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 1 Open-label Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of MK-4884 in Participants with Advanced Solid Tumors\\r\\n\\r\\nStudy centers: Bellinzona, Lausanne, St. Gallen\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\r\\n\\u003cstrong\\u003eMK-7339-002 - recruitment closed\\u003c\/strong\\u003e\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cp class=\\u0022col l9 m9 s12\\u0022\\u003eA Phase 2 Study of Olaparib Monotherapy in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer\\u003c\/p\\u003e\\r\\n\\u003cp class=\\u0022col l2 m2 offset-l1 offset-m1 s12\\u0022\\u003eStudy center: Bellinzona\\u003c\/p\\u003e\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\",\"_mco_b6_accordion_list_row_10_mco_b6_accordion_list_row_details\":\"mco_b6_accordion_list_row_details_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_10_mco_b6_accordion_list_row_image\":\"\",\"_mco_b6_accordion_list_row_10_mco_b6_accordion_list_row_image\":\"mco_b6_accordion_list_row_image_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_10_mco_b6_accordion_list_row_open\":\"0\",\"_mco_b6_accordion_list_row_10_mco_b6_accordion_list_row_open\":\"mco_b6_accordion_list_row_open_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_11_mco_b6_accordion_list_row_summary\":\"Speiser\u00f6hrenkrebs\",\"_mco_b6_accordion_list_row_11_mco_b6_accordion_list_row_summary\":\"mco_b6_accordion_list_row_summary_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_11_mcc_b6_accordion_custom_heading\":\"h5\",\"_mco_b6_accordion_list_row_11_mcc_b6_accordion_custom_heading\":\"mcc_b6_accordion_list_custom_headings\",\"mco_b6_accordion_list_row_11_mcc_b6_accordion_custom_anchor_id\":\"\",\"_mco_b6_accordion_list_row_11_mcc_b6_accordion_custom_anchor_id\":\"mcc_b6_accordion_list_custom_id\",\"mco_b6_accordion_list_row_11_mco_b6_accordion_list_row_details\":\"\\u003cstrong\\u003eMK-3475-06B \u2013 recruitment open\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 1\/2 Open-Label, Umbrella Platform Design Study of Investigational Agents With Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to PD-1\/PD-L1 Treatment: Substudy 06B.\\r\\n\\r\\nStudy centers: Chur, Geneva\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003cstrong\\u003eMK-3475-06C \u2013 recruitment open\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 1\/2 Open-Label, Umbrella Platform Design Study of MK-2870 With Pembrolizumab (MK-3475) and Chemotherapy in Participants With 1L Locally Advanced Unresectable\/ Metastatic Gastroesophageal Adenocarcinoma (Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, and Esophageal Adenocarcinoma): Substudy 06C\\r\\n\\r\\nStudy centers: Chur, Geneva\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003cstrong\\u003eMK-3475-06D \u2013 recruitment open\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 1\/2 Open-Label, Umbrella Platform Design Study to Evaluate the Safety and Efficacy of MK-2870 Plus Paclitaxel as the Second-Line Treatment of Participants With Advanced\/Metastatic Gastroesophageal Adenocarcinoma: Substudy 06D\\r\\n\\r\\nStudy centers: Chur, Geneva\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003cstrong\\u003eMK-3475-06E \u2013 recruitment open\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 1\/2 Open-Label, Umbrella Platform Design Study of Investigational Agents in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy in Participants With 1L Locally Advanced Unresectable\/Metastatic Esophageal Cancer: Substudy 06E\\r\\n\\r\\nStudy centers: Chur, Geneva\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003cstrong\\u003eMK-3475-06F \u2013 Study in start-up \\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 2 Open-Label, Umbrella Platform Design Study of Investigational Agent(s) in Participants With 2L\/3L Unresectable Locally Advanced or Metastatic Esophageal Cancer: Substudy 06F\\r\\n\\r\\nStudy centers: Chur, Geneva\",\"_mco_b6_accordion_list_row_11_mco_b6_accordion_list_row_details\":\"mco_b6_accordion_list_row_details_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_11_mco_b6_accordion_list_row_image\":\"\",\"_mco_b6_accordion_list_row_11_mco_b6_accordion_list_row_image\":\"mco_b6_accordion_list_row_image_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_11_mco_b6_accordion_list_row_open\":\"0\",\"_mco_b6_accordion_list_row_11_mco_b6_accordion_list_row_open\":\"mco_b6_accordion_list_row_open_6947uhf9ywhuj\",\"mco_b6_accordion_list_row\":12,\"_mco_b6_accordion_list_row\":\"mco_b6_accordion_list_row_6947uhf9ywhuj\"},\"mode\":\"edit\"} \/-->\n\n<!-- wp:paragraph -->\n<p>Zur \u00dcbersicht der schweizweiten Studien, die Teilnehmende suchen, <a href=\"https:\/\/www.humanforschung-schweiz.ch\/de\/\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">www.humanforschung-schweiz.ch<\/a><\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:acf\/featured-banner-block {\"name\":\"acf\/featured-banner-block\",\"data\":{\"mco_featured_banner_negative\":\"1\",\"_mco_featured_banner_negative\":\"mco_featured_banner_negative_294ytohe\",\"image\":2806,\"_image\":\"mco_featured_banner_block_image\",\"title\":\"Wir m\u00f6chten Menschen mit Krebs Hoffnung schenken\",\"_title\":\"mco_featured_banner_block_title\",\"description\":\"Wir investieren in die Entwicklung innovativer onkologischer Medikamente, um Menschen mit Krebserkrankungen zu helfen.\",\"_description\":\"mco_featured_banner_block_description\",\"content_label\":\"\",\"_content_label\":\"mco_featured_banner_block_content_label\",\"cta_one\":{\"title\":\"Mehr erfahren\",\"url\":\"https:\/\/www.msd.ch\/de\/about-msd\/areas-of-focus\/oncology\/\",\"target\":\"_blank\"},\"_cta_one\":\"mco_featured_banner_block_cta_one\",\"cta_two\":\"\",\"_cta_two\":\"mco_featured_banner_block_cta_two\"},\"mode\":\"preview\"} \/-->\n\n<!-- wp:paragraph -->\n<p><sup>CH-NON-00136, 03\/2026<\/sup><\/p>\n<!-- \/wp:paragraph -->","post_title":"Klinische Studien von MSD in der Schweiz","post_excerpt":"","post_status":"publish","comment_status":"closed","ping_status":"closed","post_password":"","post_name":"clinical-trials-in-switzerland","to_ping":"","pinged":"","post_modified":"2026-03-31 21:02:15","post_modified_gmt":"2026-03-31 19:02:15","post_content_filtered":"","post_parent":13045,"guid":"https:\/\/vip2-msd.com\/switzerland\/?page_id=2759","menu_order":1,"post_type":"page","post_mime_type":"","comment_count":"0","filter":"raw"},"story_two_selection":"select","related_content_item_two":{"ID":10010,"post_author":"974","post_date":"2023-07-13 10:11:03","post_date_gmt":"2023-07-13 08:11:03","post_content":"<!-- wp:acf\/article-hero-block {\"name\":\"acf\/article-hero-block\",\"data\":{\"date_text\":\"\",\"_date_text\":\"mco_f1_date_text\",\"share_text\":\"\",\"_share_text\":\"mco_f1_share_text\"},\"mode\":\"edit\"} \/-->\n\n<!-- wp:paragraph -->\n<p>Unser Standort in Schachen spielt eine Schl\u00fcsselrolle bei der Entwicklung neuer innovativer Medikamente. Seit seiner Gr\u00fcndung im Jahr 1976 ist der Standort kontinuierlich gewachsen. Heute arbeiten rund 490 Mitarbeitende aus 30 L\u00e4ndern in Schachen. <\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:heading -->\n<h2 class=\"wp-block-heading\">Wir zeigen, was wir in Schachen tun:<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:mccberg\/f7-listicle {\"className\":\"mt-2\"} -->\n<div class=\"wp-block-mccberg-f7-listicle mco-f7-block wrapper-story-narrower mt-2\"><!-- wp:mccberg\/f7-listicle-item {\"className\":\"mt-2\"} -->\n<div class=\"wp-block-mccberg-f7-listicle-item f7-listicle-item mt-2\"><div class=\"f7-listicle-header\"><div><\/div><div><p>01.<\/p><\/div><div><\/div><\/div><div class=\"f7-listicle-content\"><!-- wp:heading {\"level\":3} -->\n<h3 class=\"wp-block-heading\">Wir stellen biotechnologische Wirkstoffe her.<\/h3>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>In Schachen verf\u00fcgen wir \u00fcber eine biotechnische Produktion im klinischen Massstab zur Herstellung von neuen Wirkstoffen sowie \u00fcber Kapazit\u00e4ten zur sterilen Abf\u00fcllung von neuen Medikamenten.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:spacer {\"height\":\"10px\"} -->\n<div style=\"height:10px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n<!-- \/wp:spacer -->\n\n<!-- wp:image {\"id\":10253,\"sizeSlug\":\"large\",\"linkDestination\":\"none\"} -->\n<figure class=\"wp-block-image size-large\"><img src=\"https:\/\/www.msd.ch\/de\/wp-content\/uploads\/sites\/88\/2023\/07\/Stainless-Steel-Bioreactor.jpg?w=1000\" alt=\"Bioreaktor aus Edelstahl\" class=\"wp-image-10253\" \/><\/figure>\n<!-- \/wp:image --><\/div><\/div>\n<!-- \/wp:mccberg\/f7-listicle-item -->\n\n<!-- wp:mccberg\/f7-listicle-item {\"headingText\":\"02.\"} -->\n<div class=\"wp-block-mccberg-f7-listicle-item f7-listicle-item\"><div class=\"f7-listicle-header\"><div><\/div><div><p>02.<\/p><\/div><div><\/div><\/div><div class=\"f7-listicle-content\"><!-- wp:heading {\"level\":3} -->\n<h3 class=\"wp-block-heading\">Wir liefern Medikamente f\u00fcr weltweite klinische Studien.<\/h3>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>Schachen ist einer von nur zwei Standorten im globalen Netzwerk von MSD, welche klinische Studien weltweit mit neuen Arzneimitteln versorgen. Die klinischen Pr\u00fcfmuster werden hier verpackt, etikettiert und anschliessend an Klinische Zentren in der ganzen Welt verschickt. Die streng \u00fcberwachten Studien zeigen, ob die neuen Medikamente wirksam und sicher sind.<\/p>\n<!-- \/wp:paragraph --><\/div><\/div>\n<!-- \/wp:mccberg\/f7-listicle-item -->\n\n<!-- wp:mccberg\/f7-listicle-item {\"headingText\":\"03.\"} -->\n<div class=\"wp-block-mccberg-f7-listicle-item f7-listicle-item\"><div class=\"f7-listicle-header\"><div><\/div><div><p>03.<\/p><\/div><div><\/div><\/div><div class=\"f7-listicle-content\"><!-- wp:heading {\"level\":3} -->\n<h3 class=\"wp-block-heading\">Wir entwickeln analytische Methoden f\u00fcr neue Wirkstoffe und Medikamente.<\/h3>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>Analytische Entwicklung ist einer unserer Hauptbereiche. In unterschiedlichen Speziallabors untersuchen wir Zellkulturen, f\u00fchren Tests mit Bioassays durch und bieten von PCR-Analytik \u00fcber Massenspektroskopie bis hin zu biochemischen Analysen alles, was zur Entwicklung von Analysemethoden f\u00fcr neue Wirkstoffe und Medikamente n\u00f6tig ist.<\/p>\n<!-- \/wp:paragraph --><\/div><\/div>\n<!-- \/wp:mccberg\/f7-listicle-item -->\n\n<!-- wp:mccberg\/f7-listicle-item {\"headingText\":\"04.\"} -->\n<div class=\"wp-block-mccberg-f7-listicle-item f7-listicle-item\"><div class=\"f7-listicle-header\"><div><\/div><div><p>04.<\/p><\/div><div><\/div><\/div><div class=\"f7-listicle-content\"><!-- wp:heading {\"level\":3} -->\n<h3 class=\"wp-block-heading\">Wir arbeiten an Analyse-Methoden, mit denen sich ein kontinuierlicher Produktionsprozess nahtlos \u00fcberwachen und steuern l\u00e4sst.<\/h3>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>Noch sind kontinuierliche Produktionsprozesse in der pharmazeutischen Industrie die Ausnahme, da die technischen und regulatorischen Anforderungen sehr hoch sind.<\/p>\n<!-- \/wp:paragraph --><\/div><\/div>\n<!-- \/wp:mccberg\/f7-listicle-item -->\n\n<!-- wp:mccberg\/f7-listicle-item {\"headingText\":\"05.\"} -->\n<div class=\"wp-block-mccberg-f7-listicle-item f7-listicle-item\"><div class=\"f7-listicle-header\"><div><\/div><div><p>05.<\/p><\/div><div><\/div><\/div><div class=\"f7-listicle-content\"><!-- wp:heading {\"level\":3} -->\n<h3 class=\"wp-block-heading\">Wir betreiben ein forensisches Labor, in welchem Verdachtsf\u00e4lle von Arzneimittelf\u00e4lschungen untersucht werden.<\/h3>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>In Schachen betreiben wir eines von weltweit drei forensischen Laboren, mit dem Ziel, Manipulationen und F\u00e4lschungen von MSD-Produkten rasch zu erkennen. Unsere Wissenschaftler:innen arbeiten mithilfe analytischer Methoden und hochspezialisierten Instrumenten daran, F\u00e4lschungen von Originalprodukten zu unterscheiden und die Resultate gegebenenfalls vor Gericht zu vertreten, um entsprechende Strafverfolgungen als Experten zu unterst\u00fctzen. Sie arbeiten ausserdem mit daran, den F\u00e4lschungsschutz der MSD-Produkte weltweit weiter zu optimieren. <\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:spacer {\"height\":\"10px\"} -->\n<div style=\"height:10px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n<!-- \/wp:spacer -->\n\n<!-- wp:image {\"id\":10026,\"sizeSlug\":\"large\",\"linkDestination\":\"none\"} -->\n<figure class=\"wp-block-image size-large\"><img src=\"https:\/\/www.msd.ch\/de\/wp-content\/uploads\/sites\/88\/2023\/07\/MSD_lab_2.jpg?w=3840\" alt=\"\" class=\"wp-image-10026\" \/><\/figure>\n<!-- \/wp:image -->\n\n<!-- wp:spacer {\"height\":\"10px\"} -->\n<div style=\"height:10px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n<!-- \/wp:spacer --><\/div><\/div>\n<!-- \/wp:mccberg\/f7-listicle-item --><\/div>\n<!-- \/wp:mccberg\/f7-listicle -->\n\n<!-- wp:separator -->\n<hr class=\"wp-block-separator has-alpha-channel-opacity\" \/>\n<!-- \/wp:separator -->\n\n<!-- wp:pullquote {\"fontSize\":\"small\"} -->\n<figure class=\"wp-block-pullquote has-small-font-size\"><blockquote><p>\u00ab<em>Am Standort Schachen geht es nicht nur um modernste Technologie und innovative Forschung, sondern vor allem um die Menschen. Ich bin unglaublich stolz auf unser Team, das mit Leidenschaft und Engagement daran arbeitet, das Leben von Patient:innen durch bahnbrechende Entdeckungen und die Entwicklung neuer Medikamente zu verbessern. Ihr unerm\u00fcdliches Engagement macht Schachen zu einem Ort, an dem wir gemeinsam Grosses erreichen<\/em>.\u00bb<\/p><cite>DR. CORINNA LENZ, LEITERIN MSD STANDORT SCHACHEN<\/cite><\/blockquote><\/figure>\n<!-- \/wp:pullquote -->\n\n<!-- wp:separator -->\n<hr class=\"wp-block-separator has-alpha-channel-opacity\" \/>\n<!-- \/wp:separator -->\n\n<!-- wp:spacer -->\n<div style=\"height:100px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n<!-- \/wp:spacer -->\n\n<!-- wp:paragraph {\"align\":\"right\"} -->\n<p class=\"has-text-align-right\"><sup>CH-NON-02294, 07\/2023<\/sup><\/p>\n<!-- \/wp:paragraph -->","post_title":"Inside Schachen: ein Blick in unser High-Tech-Entwicklungszentrum","post_excerpt":"","post_status":"publish","comment_status":"closed","ping_status":"closed","post_password":"","post_name":"inside-schachen-ein-blick-in-unser-high-tech-entwicklungszentrum","to_ping":"","pinged":"","post_modified":"2026-02-16 20:28:08","post_modified_gmt":"2026-02-16 19:28:08","post_content_filtered":"","post_parent":0,"guid":"https:\/\/www.msd.ch\/de\/?post_type=story&p=10010","menu_order":0,"post_type":"story","post_mime_type":"","comment_count":"0","filter":"raw"},"story_three_selection":"select","related_content_item_three":{"ID":8326,"post_author":"282","post_date":"2023-04-17 20:12:34","post_date_gmt":"2023-04-17 18:12:34","post_content":"<!-- wp:acf\/article-hero-block {\"name\":\"acf\/article-hero-block\",\"data\":{\"date_text\":\"31. M\u00e4rz 2023\",\"_date_text\":\"mco_f1_date_text\",\"share_text\":\"\",\"_share_text\":\"mco_f1_share_text\"},\"mode\":\"edit\"} \/-->\n\n<!-- wp:spacer {\"height\":\"20px\"} -->\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n<!-- \/wp:spacer -->\n\n<!-- wp:paragraph {\"align\":\"left\"} -->\n<p class=\"has-text-align-left\">Anl\u00e4sslich des internationalen HPV-Awareness-Tages am 4. M\u00e4rz, lud unsere <a href=\"https:\/\/www.msd.ch\/de\/home\/about-us\/leadership\/\">Gesch\u00e4ftsleitung<\/a> alle MSD-Mitarbeitenden zu einem Lunch & Learn mit Dr. Alina Staikov ein. Sie ist Gyn\u00e4kologin und setzt sich f\u00fcr den Kampf gegen Krebs und die Aufkl\u00e4rung, Behandlung, Pr\u00e4vention und Fr\u00fcherkennung ein.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:paragraph {\"align\":\"left\"} -->\n<p class=\"has-text-align-left\">Was Krebs mit HPV zu tun hat? Humane Papillomaviren k\u00f6nnen in einigen F\u00e4llen Krebs verursachen. Das Gute ist, wer informiert ist, kann sich vor HPV sch\u00fctzen und HPV-bedingten Krebserkrankungen vorbeugen bzw. diese fr\u00fchzeitig behandeln lassen!<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:heading -->\n<h2 class=\"wp-block-heading\">Bei MSD setzen wir uns f\u00fcr die Pr\u00e4vention und Fr\u00fcherkennung von Krebs ein<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>Als eines der f\u00fchrenden Pharmaunternehmen in der Onkologie konzentrieren wir uns nicht nur auf die Aufkl\u00e4rung der \u00d6ffentlichkeit - wir leben, was wir sagen. Deshalb organisieren wir regelm\u00e4ssig interne Events, um uns weiterzubilden - in diesem Fall \u00fcber HPV und seine Auswirkungen auf die Gesundheit. Mehr als 50 Kolleg:innen von allen Schweizer Niederlassungen nutzten die Gelegenheit, von Dr. Staikov zu lernen und ihre Fragen zu stellen.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:heading -->\n<h2 class=\"wp-block-heading\">HPV k\u00f6nnen bestimmte Krebsarten verursachen<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>Dr. Staikov pr\u00e4sentierte die wichtigsten Fakten \u00fcber HPV. Sie erkl\u00e4rte, unter anderem, dass diese Viren weit verbreitet sind und selbst Teenager dar\u00fcber Bescheid wissen sollten, da sich auch Jugendliche infizieren k\u00f6nnen. Sie erkl\u00e4rte, dass fast alle Menschen im Laufe ihres Lebens mit HPV in Ber\u00fchrung kommen und was passieren kann, wenn das Virus nicht von selbst wieder verschwindet. Dr. Staikov ging deshalb besonders auf die M\u00f6glichkeiten der Vorbeugung und Fr\u00fcherkennung ein. Wir hatten auch die M\u00f6glichkeit, Fragen zu stellen, was die Veranstaltung interaktiv und lebendig machte. Unsere Botschaften f\u00fcr uns und zum Erz\u00e4hlen zuhause? Lesen Sie den n\u00e4chsten Abschnitt!<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:heading -->\n<h2 class=\"wp-block-heading\">F\u00fcnf Fakten \u00fcber HPV, die jede\/r wissen sollte<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:columns -->\n<div class=\"wp-block-columns\"><!-- wp:column {\"width\":\"66.66%\"} -->\n<div class=\"wp-block-column\" style=\"flex-basis:66.66%\"><!-- wp:list {\"ordered\":true} -->\n<ol class=\"wp-block-list\"><!-- wp:list-item -->\n<li>Humane Papillomviren (HPV) sind weit verbreitet und k\u00f6nnen bei Teenagern und Erwachsenen auftreten.<\/li>\n<!-- \/wp:list-item -->\n\n<!-- wp:list-item -->\n<li>Die Ansteckung mit den HP-Viren erfolgt von Mensch zu Mensch, durch Haut- und Schleimhautkontakt.<\/li>\n<!-- \/wp:list-item -->\n\n<!-- wp:list-item -->\n<li>HP-Viren k\u00f6nnen bestimmte Krebsarten und Krebsvorstufen verursachen.<\/li>\n<!-- \/wp:list-item -->\n\n<!-- wp:list-item -->\n<li>Zu den h\u00e4ufigsten HPV-bedingten Krebsarten geh\u00f6ren Geb\u00e4rmutterhalskrebs, Analkrebs sowie Mund- und Rachenkrebs.<\/li>\n<!-- \/wp:list-item -->\n\n<!-- wp:list-item -->\n<li>Safer Sex und Impfungen k\u00f6nnen helfen, bestimmte HPV-bedingte Krankheiten zu verhindern.<\/li>\n<!-- \/wp:list-item --><\/ol>\n<!-- \/wp:list --><\/div>\n<!-- \/wp:column -->\n\n<!-- wp:column {\"width\":\"33.33%\"} -->\n<div class=\"wp-block-column\" style=\"flex-basis:33.33%\"><!-- wp:image {\"id\":6272,\"sizeSlug\":\"large\",\"linkDestination\":\"none\"} -->\n<figure class=\"wp-block-image size-large\"><img src=\"https:\/\/www.msd.ch\/de\/wp-content\/uploads\/sites\/88\/2022\/01\/HPV-Virus-Cervical-800x800-AdobeStock_409343974.jpg?w=800\" alt=\"Illustration HPV Virus\" class=\"wp-image-6272\"\/><\/figure>\n<!-- \/wp:image --><\/div>\n<!-- \/wp:column --><\/div>\n<!-- \/wp:columns -->\n\n<!-- wp:spacer {\"height\":\"20px\"} -->\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n<!-- \/wp:spacer -->\n\n<!-- wp:paragraph {\"align\":\"center\",\"fontSize\":\"medium\"} -->\n<p class=\"has-text-align-center has-medium-font-size\"><strong>\u00ab<\/strong><em><strong>Das Wichtigste ist, dass die Menschen informiert sind. Wenn sie keine Informationen haben, k\u00f6nnen sie keine Entscheidungen treffen und haben keine Wahlm\u00f6glichkeiten.<\/strong><\/em><strong>\u00bb <\/strong><\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:spacer {\"height\":\"20px\"} -->\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n<!-- \/wp:spacer -->\n\n<!-- wp:columns -->\n<div class=\"wp-block-columns\"><!-- wp:column -->\n<div class=\"wp-block-column\"><!-- wp:image {\"id\":8335,\"sizeSlug\":\"full\",\"linkDestination\":\"none\",\"align\":\"center\",\"className\":\"is-style-default\"} -->\n<figure class=\"wp-block-image aligncenter size-full is-style-default\"><img src=\"https:\/\/www.msd.ch\/de\/wp-content\/uploads\/sites\/88\/2023\/04\/AlinaStaikov.png\" alt=\"Dr. Alina Staikov\" class=\"wp-image-8335\"\/><figcaption class=\"wp-element-caption\">Dr. Alina Staikov<\/figcaption><\/figure>\n<!-- \/wp:image --><\/div>\n<!-- \/wp:column -->\n\n<!-- wp:column -->\n<div class=\"wp-block-column\"><!-- wp:image {\"id\":8336,\"sizeSlug\":\"full\",\"linkDestination\":\"none\",\"align\":\"center\",\"className\":\"is-style-default\"} -->\n<figure class=\"wp-block-image aligncenter size-full is-style-default\"><img src=\"https:\/\/www.msd.ch\/de\/wp-content\/uploads\/sites\/88\/2023\/04\/Presentation.png\" alt=\"Pr\u00e4sentation am Welt-HPV-Tag\" class=\"wp-image-8336\"\/><figcaption class=\"wp-element-caption\">Am Event<\/figcaption><\/figure>\n<!-- \/wp:image --><\/div>\n<!-- \/wp:column -->\n\n<!-- wp:column -->\n<div class=\"wp-block-column\"><!-- wp:image {\"id\":8338,\"sizeSlug\":\"full\",\"linkDestination\":\"none\",\"align\":\"center\",\"className\":\"is-style-default\"} -->\n<figure class=\"wp-block-image aligncenter size-full is-style-default\"><img src=\"https:\/\/www.msd.ch\/de\/wp-content\/uploads\/sites\/88\/2023\/04\/Audience.png\" alt=\"Audience am Lunch & Learn \u00fcber HPV\" class=\"wp-image-8338\"\/><figcaption class=\"wp-element-caption\">Applaus f\u00fcr Dr. Staikov<\/figcaption><\/figure>\n<!-- \/wp:image --><\/div>\n<!-- \/wp:column --><\/div>\n<!-- \/wp:columns -->\n\n<!-- wp:paragraph -->\n<p>Die Veranstaltung war eine grossartige Gelegenheit f\u00fcr uns, im Team etwas zu lernen und unsere MSD-Kultur zu leben.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:spacer {\"height\":\"40px\"} -->\n<div style=\"height:40px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n<!-- \/wp:spacer -->\n\n<!-- wp:columns -->\n<div class=\"wp-block-columns\"><!-- wp:column {\"width\":\"33.33%\"} -->\n<div class=\"wp-block-column\" style=\"flex-basis:33.33%\"><!-- wp:image {\"id\":12424,\"sizeSlug\":\"large\",\"linkDestination\":\"none\"} -->\n<figure class=\"wp-block-image size-large\"><img src=\"https:\/\/www.msd.ch\/de\/wp-content\/uploads\/sites\/88\/2023\/04\/hpv-info-1.jpg?w=235\" alt=\"\" class=\"wp-image-12424\"\/><\/figure>\n<!-- \/wp:image --><\/div>\n<!-- \/wp:column -->\n\n<!-- wp:column {\"width\":\"66.66%\"} -->\n<div class=\"wp-block-column\" style=\"flex-basis:66.66%\"><!-- wp:heading {\"level\":3} -->\n<h3 class=\"wp-block-heading\">M\u00f6chten Sie mehr \u00fcber HPV wissen?<\/h3>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>Weitere Informationen f\u00fcr Eltern, Frauen und M\u00e4nner<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:paragraph {\"align\":\"left\"} -->\n<p class=\"has-text-align-left\"><a href=\"https:\/\/www.msd-gesundheit.ch\/de\/hpv-info\" target=\"_blank\" rel=\"noreferrer noopener\"><strong><span style=\"text-decoration: underline;\">Mehr entdecken<\/span><\/strong><\/a><\/p>\n<!-- \/wp:paragraph --><\/div>\n<!-- \/wp:column --><\/div>\n<!-- \/wp:columns -->\n\n<!-- wp:columns -->\n<div class=\"wp-block-columns\"><!-- wp:column {\"width\":\"66.66%\"} -->\n<div class=\"wp-block-column\" style=\"flex-basis:66.66%\"><!-- wp:heading {\"level\":3} -->\n<h3 class=\"wp-block-heading\">M\u00f6chten Sie mehr \u00fcber Geb\u00e4rmutterhalskrebs wissen?<\/h3>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>Weitere Informationen \u00fcber die Erkrankung und die Behandlung <\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:paragraph -->\n<p><a href=\"https:\/\/www.msd-gesundheit.ch\/de\/krebs\/gebaermutterhalskrebs\"><strong><span style=\"text-decoration: underline;\">Informationen f\u00fcr Frauen<\/span><\/strong><\/a><u><strong><br><\/strong><\/u><a href=\"https:\/\/www.mymsd.ch\/de\/products\/keytruda\/indikationen\/cervix\/\"><strong><span style=\"text-decoration: underline;\">Informationen f\u00fcr \u00c4rzt:innen<\/span><\/strong><\/a><br><\/p>\n<!-- \/wp:paragraph --><\/div>\n<!-- \/wp:column -->\n\n<!-- wp:column {\"width\":\"33.33%\"} -->\n<div class=\"wp-block-column\" style=\"flex-basis:33.33%\"><!-- wp:image {\"id\":6274,\"width\":\"232px\",\"height\":\"auto\",\"sizeSlug\":\"large\",\"linkDestination\":\"none\"} -->\n<figure class=\"wp-block-image size-large is-resized\"><img src=\"https:\/\/www.msd.ch\/de\/wp-content\/uploads\/sites\/88\/2022\/01\/Cervical-Cancer-gettyimages-583914445-170667a.jpg?w=800\" alt=\"Mutter und Tochter laufen nebeneinander Arm in Arm\" class=\"wp-image-6274\" style=\"width:232px;height:auto\"\/><\/figure>\n<!-- \/wp:image --><\/div>\n<!-- \/wp:column --><\/div>\n<!-- \/wp:columns -->\n\n<!-- wp:paragraph -->\n<p><sup>CH-NON-02171, 02\/2025<\/sup><\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:spacer {\"height\":\"20px\"} -->\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n<!-- \/wp:spacer -->","post_title":"Walking the talk: Lunch & Learn \u00fcber HPV","post_excerpt":"","post_status":"publish","comment_status":"closed","ping_status":"closed","post_password":"","post_name":"lunch-learn-uber-hpv","to_ping":"","pinged":"","post_modified":"2025-05-02 08:21:16","post_modified_gmt":"2025-05-02 06:21:16","post_content_filtered":"","post_parent":0,"guid":"https:\/\/www.msd.ch\/de\/?post_type=story&p=8326","menu_order":0,"post_type":"story","post_mime_type":"","comment_count":"0","filter":"raw"},"scroll-to-top":false,"subheader_title":"Brustkrebs ist die h\u00e4ufigste Krebserkrankung bei Frauen. Je fr\u00fcher Brustkrebs erkannt und behandelt wird, desto gr\u00f6sser sind die Heilungschancen. Bei MSD setzen wir uns daf\u00fcr ein, die Fr\u00fcherkennung zu st\u00e4rken. Deshalb haben wir 2022 den PINK CUBE initiiert - eine kontinuierlich wachsende Brustkrebs-Aufkl\u00e4rungsinitiative. Wir sind stolz, dass PINK CUBE mit zwei Preisen ausgezeichnet wurde.","secondary_image":false,"video_hosting_selection":"youtube","youtube_url":"","video_accessible_name":"","primary_cta":"Read more","primary_cta_aria_label":"","secondary_cta":"","secondary_cta_aria_label":"","mcc_page_job_number":"","show_image_captions":false,"related_content_item_one_aria_label":"","related_content_item_two_aria_label":"","related_content_item_three_aria_label":""}},"_links":{"self":[{"href":"https:\/\/www.msd.ch\/de\/wp-json\/wp\/v2\/story\/12331","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.msd.ch\/de\/wp-json\/wp\/v2\/story"}],"about":[{"href":"https:\/\/www.msd.ch\/de\/wp-json\/wp\/v2\/types\/story"}],"version-history":[{"count":74,"href":"https:\/\/www.msd.ch\/de\/wp-json\/wp\/v2\/story\/12331\/revisions"}],"predecessor-version":[{"id":13692,"href":"https:\/\/www.msd.ch\/de\/wp-json\/wp\/v2\/story\/12331\/revisions\/13692"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.msd.ch\/de\/wp-json\/wp\/v2\/media\/12343"}],"wp:attachment":[{"href":"https:\/\/www.msd.ch\/de\/wp-json\/wp\/v2\/media?parent=12331"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.msd.ch\/de\/wp-json\/wp\/v2\/tags?post=12331"},{"taxonomy":"content_topic","embeddable":true,"href":"https:\/\/www.msd.ch\/de\/wp-json\/wp\/v2\/content_topic?post=12331"},{"taxonomy":"Admin Field","embeddable":true,"href":"https:\/\/www.msd.ch\/de\/wp-json\/wp\/v2\/admin_field?post=12331"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}